Continuous pharmaceutical manufacturing and its contemporary regulatory insights
Discover Applied Sciences · 26.09.2025 · 7 (10)
DOI: 10.1007/s42452-025-07712-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Applied Sciences, online erschienen am 26.09.2025. Verfasst von Atlaw Abate Alemie und 5 weiteren Autor:innen. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nowadays, continuous manufacturing is a widely accepted production system in the pharmaceutical industry, as it provides several advantages over the conventional approach. The production system offers a more efficient, consistent, and uninterrupted process integrated with a real-time production system. This improvement results in high-quality products, increased uniformity, and minimized variation during production. Specifically, continuous manufacturing reduces production time by nearly 90%, improves product quality by 40%, and enhances production efficiency by 90%. Moreover, it minimizes energy and water consumption by 25–50% and requires 30–50% less working space. Consequently, it reduces manufacturing costs and supports an environmentally friendly and sustainable production practice. The transition from conventional to continuous production processes further enhances broader manufacturing capabilities and minimizes essential stockouts by improving the market supply chain during pandemics and public health emergencies. Currently, over 15 pharmaceutical products are manufactured through a continuous process and have obtained approval from the U.S. FDA, supported by regulatory frameworks including ICH Q13, which enhances universally harmonized practice. Nevertheless, the adoption of continuous manufacturing still faces numerous challenges, including regulatory approval hurdles, integration with conventional systems, requirements for consistent compliance, advanced production techniques, and the need for various stakeholder partnerships. Hence, the main objective of this review is to navigate the existing knowledge, opportunities, challenges, and regulatory approval barriers, and to highlight potential gaps related to the continuous manufacturing process. This comprehensive review of literature was conducted through searches in standard databases such as PubMed, Google Scholar, ScienceDirect, Medline, and Elsevier. The results indicate the need for harmonized and integrated efforts across multiple disciplines to design efficient strategies for overcoming regulatory hurdles and enabling wider implementation of the continuous manufacturing process.
Zitieren
APA
Alemie, A. A., Siraj, E. A., Yayehrad, A. T., Tafere, C., Tessema, T. A., & Belete, A. (2025). Continuous pharmaceutical manufacturing and its contemporary regulatory insights. Discover Applied Sciences, 7(10). https://doi.org/10.1007/s42452-025-07712-9
Vancouver
Alemie AA, Siraj EA, Yayehrad AT, Tafere C, Tessema TA, Belete A. Continuous pharmaceutical manufacturing and its contemporary regulatory insights. Discover Applied Sciences. 2025;7(10). doi:10.1007/s42452-025-07712-9
BibTeX
@article{Alemie2025,
author = {Alemie, Atlaw Abate and Siraj, Ebrahim Abdela and Yayehrad, Ashagrachew Tewabe and Tafere, Chernet and Tessema, Tewodros Ayalew and Belete, Anteneh},
title = {Continuous pharmaceutical manufacturing and its contemporary regulatory insights},
journal = {Discover Applied Sciences},
year = {2025},
volume = {7},
number = {10},
doi = {10.1007/s42452-025-07712-9}
}
EUVIMED